



Financial Tear Sheet

Corporate Profile

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com (<http://www.alkermes.com>).

IR Contacts

Sandy Coombs
Co-Head, Investor Relations
Alkermes, Inc.
Phone: 1 781-609-6377
E-mail: Sandra.Coombs@alkermes.com (<mailto:Sandra.Coombs@alkermes.com>)

Eva Stroynowski
Co-Head, Investor Relations
Alkermes, Inc.
Phone: 1 781-609-6823
E-mail: eva.stroynowski@alkermes.com (<mailto:eva.stroynowski@alkermes.com>)

Stock Performance

ALKS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$34.03
Change (%)	0.46 (1.33%)
Volume	701,501
52 Week Low	\$32.61
Market Cap	\$5,287,676,242
Rolling EPS	-0.90
PE Ratio	N/A
Shares Outstanding	155,382,787

Data as of 11/19/18 4:00 p.m. ET



Recent Headlines & Events

- 11/06/18 - 4:01 p.m.
Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences (phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2375640)
- 11/06/18 - 8:01 a.m.
Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting (phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2375550)
- 11/01/18 - 6:25 p.m.
Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2375026)

There are currently no events scheduled.

Mean Recommendation: 2.5

Unable to fulfill request.



Sell Strong Buy

SEC Filings

Year Filter

All Years

Filing Date	Form
11/09/18	8-K (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsaW5LnhtbD9yZXBvPXRlbmsmaXBhZ2U9MT1NDM0ODEmc3Vic2lkPTU3JmI4YnJsPXRydWU%3d&ListAll=1)
11/02/18	4 (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsaW5LnhtbD9yZXBvPXRlbmsmaXBhZ2U9MT1Mj50TAmc3Vic2lkPTU3JmI4YnJsPXRydWU%3d&ListAll=1)
11/02/18	8-K (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsaW5LnhtbD9yZXBvPXRlbmsmaXBhZ2U9MT1MjY1MTAmc3Vic2lkPTU3JmI4YnJsPXRydWU%3d&ListAll=1)
10/30/18	8-K (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsaW5LnhtbD9yZXBvPXRlbmsmaXBhZ2U9MT1MTgwMDgmc3Vic2lkPTU3JmI4YnJsPXRydWU%3d&ListAll=1)

Corporate Governance

Richard F. Pops Chairman and Executive Officer

Shane Cooke President

Kathryn L. Biberstein Senior Vice Chief Legal Officer, and Alkermes pi

Madeline D. Coffin Vice President, Resources

Elliot W. Ehrich, M.D. Executive Vice President, and Chief Medical Officer

James M. Frates Senior Vice President, Finance

Georgianna Harris, Ph.D. Vice President, Regulatory

Blair C. Jackson Vice President, Development

Michael J. Landine Senior Vice President, Corporate Development

Mark Namchuk, Ph.D. Senior Vice President, Research, and Nonclinical Development

Peter Norman Vice President, Government Affairs

Rebecca J. Peterson Senior Vice President, Corporate Communications

Gordon G. Pugh Senior Vice President, Chief Operating Officer, and Chief Financial Officer


Srdjan Stankovic, M.D., MSPH Senior Vice President, Clinical Development, and Medical Affairs

Mark Stejbach Senior Vice President, Chief Compliance Officer

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	0	.00	0.0	0
Mutual Fund	0	.00	0.0	0
Insider *	0	.00	0.0	0

*Insider values reflect direct beneficial ownership.

Powered by  Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed